Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

The Bridge to Good Health Care

JMS CO.,LTD.

[Reference Translation]

November 7, 2025

Company name: JMS Co., Ltd.
Name of representative: Ryuji Katsura, President and Representative Director
(Securities code: 7702; Tokyo Stock Exchange)
Inquiries: Yoshiki Ochiai , Executive Officer, Head of Corporate Affairs Division
(Telephone: +81-82-243-5844)

Notice regarding Differences between Consolidated Financial Forecasts and Actual Results for the First Half of the Fiscal Year Ending March 31, 2026 and Revision of Forecast for Consolidated Financial Results for the Full Fiscal Year.

Announcement of the following discrepancies between the consolidated financial results forecast for the first half of the fiscal year ending March 31, 2026 which was announced on May 9, 2025, and the actual results for the same period disclosed today.

In addition, we would like to announce the following revisions made to its forecast for the consolidated financial results for the full fiscal year ending March 31, 2026, in view of the trend in its recent business performance.

1. Difference between Consolidated Financial Forecast and Actual Results for the First Half of the Fiscal Year Ending March 31, 2026 (April 1, 2025 - September 30, 2025)

(Unit: million yen)

	Net sales	Operating profit	Ordinary profit	Profit attributable to owners of parent	Earnings per share
Forecast previously announced (A)	33,800	350	300	100	4.08 yen
Actual results announced today (B)	32,216	(19)	(46)	(190)	(7.78) yen
Difference (B − A)	(1,583)	(369)	(346)	(290)	
Difference (%)	(4.7)	—	—	—	
<Reference>Actual results for first half of previous fiscal year ended March 31, 2025	33,830	155	(118)	(258)	(10.58) yen

2. Revision to consolidated Financial Forecast for the fiscal year ending March 31, 2026 (April 1, 2025 to March 31, 2026)

(Unit: million yen)

	Net sale	Operating profit	Ordinary profit	Profit attributable to owners of parent	Earnings per share
Forecast previously announced (A)	68,000	900	600	200	8.16 yen
Forecast announced today (B)	66,000	500	300	100	4.08 yen
Difference (B − A)	(2,000)	(400)	(300)	(100)	
Difference (%)	(2.9)	(44.4)	(50.0)	(50.0)	
<Reference> Actual results for previous fiscal year ended March 31, 2025	69,749	872	514	89	3.65 yen

3. Reasons for the difference and revision

For the interim consolidated accounting period ending March 2026, net sales fell short of the previous forecast. While domestic sales of Closed Drug Mixing/Infusion Systems and Dysphagia-related products progressed steadily, orders for Apheresis Kits and Blood Bags decreased due to inventory adjustments by major overseas customers.

In terms of profitability, we implemented initiatives to improve earnings, such as passing on higher costs through price increases due to inflation and streamlining unprofitable items; however, partly due to the impact of lower capacity utilization at overseas production sites resulting from a decrease in orders, operating income, ordinary income, and interim profit attributable to owners of parent all fell short of the previous forecast.

Regarding the full-year consolidated earnings forecast for the fiscal year ending March 2026, we have revised the previously announced figures. This revision reflects our continued implementation of profit improvement measures, including expanding sales domestically and internationally, reviewing prices, reducing manufacturing expenses, and cutting expenses through efficient business operations. It also takes into account the results for the interim consolidated accounting period and the persistent high level of raw material prices.

*The above forecast is based on currently available information as of the announcement of this material and actual results may differ from the projected figures due to various factors.

END